Phase 3 trial shows lanadelumab to be effective in reducing hereditary angioedema attacks

A phase 3 clinical trial finds that injections of the monoclonal antibody drug lanadelumab reduced attacks of hereditary angioedema -- a rare, potentially life-threatening disorder.